Alert Number: I-022825-PSA

Safety Concerns Related to Fraudulent Compounding Practices Associated with Weight Loss Drugs


The Federal Bureau of Investigation (FBI) warns the public of noncompliant healthcare providers, to include pharmacies, weight loss clinics, and medical spas, engaging in fraudulent compounding practices by unlawfully misrepresenting compounded weight loss drugs. These misrepresented drugs can pose safety risks and significant health consequences to patients, such as gastrointestinal disorders, nervous system disorders, cardiac disorders, psychiatric disorders, and death.

Noncompliant healthcare providers are selling fraudulently compounded drugs claiming to contain semaglutide, the active ingredient in Ozempic and Wegovy, in combination with other ingredients. Some healthcare providers are using compounded mixtures of unknown drugs that do not contain semaglutide, drugs with high levels of impurities, and unsafe or unapproved drugs.

Tips to Protect Yourself

  • Avoid suspiciously low prices of weight loss drugs sold by unlicensed healthcare providers.
  • Be cautious when purchasing any pharmaceutical drugs online and buy only from licensed pharmacies.
  • Consult with your medical provider before using any pharmaceutical weight loss drugs.

Report It

If you believe you have been a victim of a similar fraudulent activity, please file a report with the FBI's Internet Crime Complaint Center at www.ic3.gov. Be sure to include as much information as possible: